Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care-Reference-Cited by-同舟云学术

Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care

Published:2018-06-05 Issue:6 Volume:2018 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Candy Bridget¹,Jones Louise¹,Vickerstaff Victoria¹,Larkin Philip J²,Stone Patrick³

Affiliation:

1. Marie Curie Palliative Care Research Department, UCL Division of Psychiatry; 6th Floor, Maple House 149 Tottenham Court Road London UK W1T 7NF

2. UCD College of Health Sciences; UCD School of Nursing, Midwifery and Health Systems and Our Lady's Hospice and Care Services; Dublin Ireland

3. Marie Curie Palliative Care Research Department, UCL Division of Psychiatry; Division of Psychiatry; Room 119, First Floor, Charles Bell House 67-73 Riding House Street London UK W1W 7EJ

Publisher

Wiley

Subject

Pharmacology (medical)

Reference75 articles.

1. A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain;Ahmedzai;Palliative Medicine,2012

2. Center for Drug Evaluation and Research Medical Review Application number: 205777Orig1s000 www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf

3. US Food Drug Administration Center for Drug Evaluation and Research Risk Assessment and Risk Mitigation Review. Product oxycodone/naloxone extended-release tablets www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000RiskR.pdf

4. Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension;Bull;Journal of Palliative Medicine,2015

5. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone/naloxone (up to 160/80 mg daily) vs oxycodone PR;Dupoiron;European Journal of Pain,2017

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The safety and effectiveness of naldemedine for opioid-induced constipation in patients with advanced cancer in real-world palliative care settings: a multicenter prospective observational study;Supportive Care in Cancer;2024-07-10

2. Palliative and Supportive Medicine in Gastrointestinal Oncology;Gastrointestinal Oncology ‐ A Critical Multidisciplinary Team Approach 2e;2024-01-23

3. Bowel Management Protocol;Professional Case Management;2024-01

4. Effect of multi-dimensional nursing combined with early postoperative activity on the prognosis of patients undergoing laparoscopic radical gastrectomy for gastric cancer;INT J RADIAT RES;2023

5. Effect of multi-dimensional nursing combined with early postoperative activity on the prognosis of patients undergoing laparoscopic radical gastrectomy for gastric cancer;International Journal of Radiation Research;2023-06-01